This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
2025 Health Leadership Conference takes on The Future of Leadership January 22, 2025 By: Leah Poffenberger, Senior Manager, Communications Leadership health care often comes with unique challenges in an ever-changing ecosystem. To learn more about the 2025 Health Leadership Conference, visit the conference website.
In 2025, pharmaceutical trends are redefining how brands connect with healthcare professionals (HCPs), patients, and stakeholders. With machine learning and big data analytics, companies can now predict market trends, enhance drugdevelopment, and create hyper-personalized campaigns.
Audience-favorite sessions included a discussion led by Michaeleen Crowel and Martin Riser from the S-3 Group outlining how the recent elections impact the lame duck session and health policy in early 2025. We look forward to building on these conversations at the 2025 Washington Representatives Retreat in Annapolis on November 20 – 21!
NHC Submits Comments on FDA Draft Guidance on AI to Support Regulatory Decision-Making for Drugs/Biologics (PDF) April 7, 2025 Dockets Management Staff U.S. 14 In addition, sponsors should ensure that the datasets used to develop AI models reflect the intended patient population and disease variations.
The company believes this approach has the potential to revolutionise drug discovery in therapeutic areas with unclear mechanisms or limited success using traditional methods. AI has already proven a boon in other areas of drugdevelopment in recent years with the Covid-19 pandemic motivating innovation.
This article will cover the most important areas of AI influence on the pharma industry and new drugsdevelopment. From life-saving drugs discovery, development, and production to clinical trials, communication, and drug target identification — AI pharmaceutical is a definite game-changer.
The company believes this approach has the potential to revolutionise drug discovery in therapeutic areas with unclear mechanisms or limited success using traditional methods. AI has already proven a boon in other areas of drugdevelopment in recent years with the Covid-19 pandemic motivating innovation.
We believe in the power of high-quality patient engagement that is characterized by sustained, reciprocal communication between patients and decision- makers. The NHC urges CMS to engage collaboratively with MA plans to track the clarity, accuracy, and transparency of marketing materials and communications.
“In a situation where most of the development of treatments in Korea is mostly centred on cancer and metabolic diseases, I noticed that there weren’t any companies that were focusing on sensory diseases.”. Kim says the Dry Eye Disease market is large and growing, with analysts predicting it will hit $6 billion USD by 2025. Conclusion.
10: External Data Submission Timing The NHC understands the tight timeline for the drug selection and price negotiation processes. Including this information in the explanation will help patient advocates develop the most useful data for future negotiations. He is reachable via e- mail at egascho@nhcouncil.org. Sincerely, Randall L.
FDA strongly encourages sponsors to discuss plans for a waiver early in the planning stages of the study or development program. If FDA determines that a waiver will be issued, it may consider public communications about the decision. Some unanswered questions remain.
Several drugdevelopment trends are driving injectables demand. This includes the rising number of biologic drugs on the market, which are mostly administered parenterally. From 2025, it will be substituted with a new chapter on functional tests for the complete system.”
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content